Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A CASE OF CASTRATION-RESISTANT PROSTATE CANCER ASSOCIATED WITH HEREDITARY BREAST-OVARIAN CANCER SYNDROME SHOWING LONG-TERM RESPONSE TO A POLY-ADP RIBOSE POLYMERASE INHIBITOR].

Hinyokika kiyo. Acta urologica Japonica·2026
Same author

One-year clinical remission with tezepelumab in severe asthma: TERESA single-arm prospective study.

The Journal of allergy and clinical immunology·2026
Same author

[Negative Pressure Wound Therapy for Fournier's Gangrene in the Inguinal Region : A Case Report].

Hinyokika kiyo. Acta urologica Japonica·2026
Same author

Lipid Extraction from Wet Polymer-Flocculated <i>Chlorella sorokiniana</i> Using Liquefied Dimethyl Ether without Centrifugation and Drying Pretreatment.

ACS omega·2025
Same author

Performance of GPT-4o combined with retrieval-augmented generation on nutritionist licensing exam questions.

Endocrine journal·2025
Same author

Investigating Thermoelectric Properties of GeTe Alloys with Multi Element Doping: Insights from High-Entropy Engineering.

ACS omega·2025

Related Experiment Video

Updated: Jun 19, 2026

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Structural changes in alpha1-adrenoceptor antagonist-treated human prostatic stroma.

Tetsuya Imamura1, Kenichiro Ishii, Hideki Kanda

  • 1Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.

Clinical and Experimental Medicine
|October 15, 2009
PubMed
Summary
This summary is machine-generated.

Alpha1-blockers are common for benign prostatic hyperplasia (BPH), but resistance can occur. Increased collagen in prostate tissue may explain why alpha1-blockers become less effective, necessitating surgery.

Related Experiment Videos

Last Updated: Jun 19, 2026

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Area of Science:

  • Urology
  • Pharmacology
  • Pathology

Background:

  • Alpha1-adrenoceptor antagonists (alpha1-blockers) are first-line treatments for benign prostatic hyperplasia (BPH).
  • Treatment resistance and the need for surgical intervention are common in BPH management.
  • Prostatic tissue structural changes may contribute to alpha1-blocker resistance.

Purpose of the Study:

  • To investigate the role of prostatic stroma composition in alpha1-blocker treatment resistance in BPH.
  • To compare collagen fiber content in BPH patients with varying treatment responses.

Main Methods:

  • Masson's trichrome staining was used to quantify collagen fibers in prostatic tissue samples.
  • Tissue samples were analyzed from an untreated group, an alpha1-blocker-treated group, and a surgically treated group.
  • Collagen fiber share was compared across the groups, with a focus on cases with high collagen content (≥70%).

Main Results:

  • The mean collagen fiber share was significantly higher in the alpha1-blocker-treated group (72.1%) and the surgically treated group (72.2%) compared to the untreated group (62.2%).
  • A higher proportion of patients with high collagen fiber share (≥70%) was observed in both alpha1-blocker-treated groups compared to the untreated group.
  • These findings suggest a link between increased collagen accumulation and reduced efficacy of alpha1-blockers.

Conclusions:

  • Accumulation of collagen fibers in the prostatic stroma may be a contributing factor to alpha1-blocker treatment resistance in BPH.
  • Altered tissue architecture, specifically increased fibrosis, could impair the effectiveness of alpha1-blockers.
  • Further research into stromal composition may reveal new therapeutic targets for BPH.